COMPARISON OF BUTYRYLPERAZINE AND TRLFLUOPERAZINE IN CHRONIC SCHIZOPHRENIC SUBJECTS
Abstract
Butyrylperazine, a new phenothiazine of the piperazine series, was compared with trifluoperazine in a 3-month study involving 44 chronic schizophrenic patients. The study employed a double-blind, cross over design using a fixed dosage regimen of both drugs. A 2-week placebo interval was used prior to the cross over and at the completion of the study.
There were no significant differences in therapeutic effectiveness or incidence of side reactions between the drugs. Similarities between the drugs were greater than differences.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
